Precision Biosciences Inc(DTIL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 PM ET (Korea 10/30 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.85 | Insider Own | 13.49% | Shs Outstand | 26.4M | Perf Week | 9.73% |
| Market Cap | 0.21B | Forward P/E | - | EPS next Y | 20.98% | Insider Trans | 0.13% | Shs Float | 23.9M | Perf Month | 18.85% |
| Enterprise Value | 0.15B | PEG | - | EPS next Q | -0.85 | Inst Own | 66.66% | Short Float | 9.87% | Perf Quarter | 6.44% |
| Income | -0.05B | P/S | 4.56 | EPS this Y | -0.96% | Inst Trans | 8.36% | Short Ratio | 9.08 | Perf Half Y | 4.06% |
| Sales | 0.05B | P/B | 4.34 | EPS next 5Y | 17.58% | ROA | -45.66% | Short Interest | 2.36M | Perf YTD | 78.85% |
| Book/sh | 1.71 | P/C | 2.35 | EPS past 3/5Y | 54.31% 43.45% | ROE | -135.15% | 52W High | -22.66% ($9.62) | Perf Year | -11.74% |
| Cash/sh | 3.17 | P/FCF | - | Sales past 3/5Y | 10.93% 7.13% | ROIC | -74.69% | 52W Low | 110.76% ($3.53) | Perf 3Y | -13.56% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 67.74% | Gross Margin | 94.24% | Volatility(W/M) | 8.21% 6.44% | Perf 5Y | -97.39% |
| Dividend TTM | - | EV/Sales | 3.24 | Sales Y/Y TTM | 3472.96% | Oper. Margin | -80.78% | ATR (14) | 0.44 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.82 | EPS Q/Q | 40.69% | Profit Margin | -119% | RSI (14) | 63.02 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.82 | Sales Q/Q | -100% | SMA20 | 14.63% ($6.49) | Beta | 1.39 | Target Price | $29.4 |
| Payout | - | Debt/Eq | 0.62 | Earnings | 2026/8/6 | SMA50 | 7.29% ($6.93) | Rel Volume | 0.64 | Prev Close | $7.47 |
| Employees | 68 | LT Debt/Eq | 0.58 | EPS/Sales Surpr. | -56.72% -100% | SMA200 | 14.05% ($6.52) | Avg Volume(3M) | 0.26M | Price | $7.44 |
| IPO | 2019/3/28 | Option/Short | Yes/Yes | Trades | 1442 | Volume | 165,720 | Change | -0.4% |
🧬 A US biotech company developing therapeutics for rare diseases, oncology, and viral diseases based on its proprietary gene-editing platform. Founded in the US in 2006 and listed on Nasdaq, the company possesses differentiated technical expertise in disease-targeting gene editing.
Over the past 1 year, roughly in the middle
23% below its 1-year high.
Traded less than usual. That is 64% of its average volume.
DTIL has a sound balance sheet but weak earning power
Of every $100 in sales, $80.78 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -1.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $456. Peers typically go for $1,089.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.4%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 66.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #299 of 594 in the industry
Based on market cap of $205M.
PALI#297 Palisade Bio Inc $207M PER - 
ARTV#298 Artiva Biotherapeutics Inc $207M PER - DTIL#299 Precision Biosciences Inc $205M PER - 
RNAC#300 Cartesian Therapeutics Inc $204M PER - 
PRQR#301 ProQR Therapeutics N.V $203M PER - 
FAQ
What kind of company is DTIL?
DTIL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DTIL?
The market cap of DTIL is approximately $205M, ranking 3,999 within its sector.
What is the 52-week high and low for DTIL?
DTIL has recorded a 52-week high of $9.62 and a low of $3.53.
